A global perspective of Lp(a) levels in patients with coronary heart disease - Implications for risk factor control & future trials from the INTERASPIRE Study

30 August 2024 (08:00 - 17:30)

Organised by:

Sign in to view the resources

Sign in to view the resources

About the speaker

Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail

LDL-Cholesterol levels and lipid lowering therapy in secondary prevention patients: preliminary data from BRING-UP Prevention Study

Doctor A. Maggioni (Florence, IT)

Presentation thumbnail

Suboptimal Lipid Measurement and Statin Use after Percutaneous Coronary Intervention is associated with Increased Mortality: Results of a Real World Registry of 76,264 Patients in NW London

Doctor M. Akhtar (London, GB)

Presentation thumbnail

Intensive, early and sustained lowering of atherogenic lipoproteins after myocardial infarction and long-term prognosis: a nationwide cohort study of myocardial infarction patients

Ms J. Schubert (Uppsala, SE)

Presentation thumbnail

Association of early versus late use of combination lipid-lowering therapy with major cardiovascular outcomes after myocardial infarction: data from the SWEDEHEART registry

Associate Professor M. Leosdottir (Malmo, SE)

Presentation thumbnail

Optimising oral lipid-lowering therapy regimens in high and very high-risk statin intolerant patients with dyslipidaemia: A French real-world simulation

Professor F. Schiele (Besancon, FR)

Access the full session

Session thumbnail

Registries, observational, and other studies on lipids

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

You may be interested in

Webinar

Unmet needs in lipid management: treatment goals and how to achieve them

Congress Presentation

Lipid control in cardiovascular patients

Webinar

Risk assessment and lipid management in primary prevention

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources